NUS Magnetic Lipid Nanoparticles Revolutionize Targeted mRNA Delivery for Cancer Immunotherapy

Revolutionizing mRNA Delivery: NUS Breakthrough with Magnetic Lipid Nanoparticles

Singapore's National University of Singapore (NUS) has made headlines with a groundbreaking advancement in nanomedicine: magnetic lipid nanoparticles (mLNPs) designed for targeted messenger RNA (mRNA) delivery. This innovation, detailed in a recent publication, promises to transform how mRNA therapeutics are administered, particularly for applications like cancer immunotherapy. By harnessing external magnetic fields, researchers can direct these nanoparticles to specific organs, minimizing off-target effects and enhancing efficacy.

The study, led by NUS scientists Liqiang Yang and Jiong-Wei Wang from the Yong Loo Lin School of Medicine's Cardiovascular Research Institute and Nanomedicine Translational Research Programme, collaborates with experts from University Medical Center Utrecht. Published on February 19, 2026, in ACS Applied Materials & Interfaces, it demonstrates how mLNPs loaded with luciferase mRNA can be precisely guided to the heart and lungs in mice, bypassing traditional liver accumulation.

The Challenges of mRNA Therapeutics in Modern Medicine

mRNA therapeutics, popularized by COVID-19 vaccines, encode instructions for cells to produce specific proteins, offering rapid development for vaccines and treatments. However, key hurdles persist: rapid clearance from the bloodstream, endosomal entrapment preventing release, and nonspecific distribution leading to off-target effects. Conventional lipid nanoparticles (LNPs), the gold standard for mRNA delivery, predominantly accumulate in the liver, limiting applications for non-hepatic targets like tumors or immune cells crucial for cancer immunotherapy.

In Singapore, where cancer incidence is rising—with over 32,000 new cases annually according to the National Cancer Centre Singapore—targeted delivery is vital. mRNA-based cancer vaccines aim to stimulate tumor-specific T-cell responses, but inefficient targeting reduces potency and increases toxicity risks.

How Magnetic Lipid Nanoparticles Work: A Step-by-Step Breakdown

Magnetic lipid nanoparticles build on standard LNPs by incorporating magnetic iron oxide cores within lipid shells. Here's the process:

• Synthesis: Iron oxide nanoparticles are encapsulated in ionizable lipids, cholesterol, and PEG-lipids, forming stable mLNPs that protect mRNA.
• Loading: mRNA (e.g., encoding luciferase or antigens) is complexed electrostatically.
• Targeting: An external static magnetic field (e.g., neodymium magnets) applied to target areas like the chest redirects mLNPs via magnetophoresis, enhancing vascular retention.
• Uptake and Expression: mLNPs enter cells, escape endosomes, and translate mRNA into proteins, confirmed by bioluminescence in vivo.

This non-invasive guidance enables organ-specific expression, a leap from passive or ligand-based targeting.

NUS Study Design and Experimental Results

In the NUS-led experiments, mice received intravenous mLNPs or non-magnetic LNPs (nLNPs) loaded with luciferase mRNA. Without magnets, both accumulated in the liver, as expected. With magnets positioned over heart/lung regions:

• Bioluminescence signals surged in heart (3-5x) and lungs (4-6x).
• Liver and spleen signals dropped 50-70%.

In vitro, mLNPs showed efficient eGFP expression and Cre recombinase activity under magnetic fields. Supporting data included UV-vis spectroscopy, cellular uptake tracking, and mRNA sequencing, confirming stability and redirection.Read the full paper

Bridging to Cancer Immunotherapy: Tailored Tumor Targeting

While the study focused on heart/lung, mLNPs hold immense promise for cancer immunotherapy. mRNA vaccines encoding neoantigens can prime dendritic cells and T-cells. Magnetic guidance could target lymph nodes or tumors directly, boosting efficacy. NUS's prior work, like safer LNPs for cancer vaccines (2022), complements this—reducing liver toxicity while enhancing immune responses.

The 2025 NUS-Tsinghua EB-LNP platform targeted lymph nodes for melanoma/HPV cancers, eliciting strong T-cell responses at lower doses. Combining magnetic control could revolutionize personalized vaccines, vital in Singapore's aging population facing rising cancers.

NUS Nanomedicine: Singapore's Global Leader

NUS's Nanomedicine Translational Research Programme drives innovations like mLNPs, positioning Singapore as Asia's biomed hub. With S$37 billion in RIE2030 funding, initiatives support mRNA tech amid post-COVID momentum. Collaborations with Utrecht exemplify Singapore's international edge.Explore higher ed jobs in Singapore biomed

Statistics: Singapore's biomed sector employs 25,000, contributes 5% GDP; NUS ranks top 10 globally in pharmacology/pharmacy (QS 2026).

Real-World Impacts and Stakeholder Perspectives

Clinicians praise precision: reduced doses mean fewer side effects. Patients benefit from localized therapy, minimizing systemic inflammation. Industry sees scalable manufacturing potential, akin to COVID LNPs (Moderna/Pfizer produced billions).

Challenges: Magnet strength for deep tumors, biocompatibility long-term. Experts like Prof. Jiong-Wei Wang envision clinical trials soon.Career advice for nanomed researchers

Future Outlook: From Bench to Bedside

mLNPs pave way for magnetic tumor targeting, combining with CRISPR/mRNA combos. Singapore's A*STAR-NUS ecosystem accelerates translation; trials could start 2027-28. Global market: mRNA therapeutics to hit US$100B by 2030.

Risks: Regulatory hurdles for magnets; solutions via FDA precedents. Actionable: Aspiring researchers, pursue NUS PhDs; industry, partner via AcademicJobs recruitment.

Singapore's Biomedical Ecosystem and Career Opportunities

Singapore invests heavily: Biomedical manufacturing hub, EDB supports startups. NUS grads lead; roles in drug delivery booming. Check faculty positions, professor ratings.

Statistics: 1,500 biomed patents yearly; NUS outputs 20% Singapore research.

Photo by Shubham Dhage on Unsplash

Conclusion: A Magnetic Leap Forward

NUS's mLNPs herald precise mRNA era, boosting cancer immunotherapy. Explore careers at university jobs, advice at higher ed career advice, rate profs at Rate My Professor. Singapore leads; join the revolution.Post a job